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Introduction.  
Today it can be considered as already established 
fact, that tumours are genetic diseases whose pathogenetic 
substrate is damage to specific sections of DNA. These 
sections are responsible for the mechanisms of control of 
cell proliferation and differentiation. As a result, this can 
lead to tumour formation [1]. 
Over the past 20 years, the breast cancer incidence 
rate has increased by an average of 40% and pathology has 
become the most common cancer affecting every tenth 
woman in the life expectancy range from 13 to 90 years 
[2]. 
According to experts from the National Cancer 
Institute, a diagnosis of breast cancer (BC) by the end of 
2020 may become a reality for almost 17% of Ukrainian 
women, which gives reason to view it as a socially 
significant epidemiological problem. According to the 
International Agency for Research on Cancer (IARC) at 
WHO, more than 1.7 million women are diagnosed with 
breast cancer annually. In Ukraine, according to the 
National Cancer Registry, in 2013, BC was first identified 
in 16,624 women (in 2012 - 16,660), which is 72.2 cases 
(in 2012 - 67) for every 100,000 women in the country. The 
global death toll from this disease is growing and is killing 
more than 500,000 women worldwide annually. In 2013 in 
Ukraine, 7429 women died with this diagnosis (7558 in 
2012) [3]. 
Uniform classification of breast pathology, 
including fibrocystic mastopathy (FCM), is presented in 
sections N60-N64 of the International Statistical 
Classification of Diseases (ICD-10), which allows 
comparisons of the prevalence of this pathology in 
different regions of the world. 
The greatest achievement of theoretical oncology 
in the second half of XX century was the disclosure of the 
role of chronic inflammation as a precancerous condition. 
In chronic inflammation, begin to proliferate stem cells, 
transforming already into the stem cells of a malignant 
tumour. "Inflammatory cells" allocate growth factors for 
tumour cells, as well as angiogenic factors that stimulate 
the formation of tumour in the microcirculatory 
bloodstream. Due to chronic inflammation, the stroma of 
the malignant tumour is formed. Permanent inflammation 
due to ongoing necrosis in the tumour provides the cells 
with angiostimulating and growth factors.  
The path from the origin of the tumour cell to the 
progression of the disease is determined by the consistent 
implementation of the patterns inherent in tumour growth 
(carcinogenesis). It is generally accepted characteristic of 
the development of cancer in the form of four successive 
stages: initiation, promotion, evasion of differentiation and 
progression [5]. 
The most studied physiological promoters of 
proliferation in the mammary gland to date are the steroid 
ovarian hormone estradiol and its metabolites [4]. 
Homeostasis of breast tissues is the result of 
equilibrium between proliferation, differentiation and 
apoptosis of its cellular composition, which depends on the 
optimal ratio, both in serum and in breast tissues, the 
concentration of the major sex hormones (estrogen and 
progesterone), which provide the above effects. 
An essential step in a comprehensive approach to 
reducing the incidence of BC was the unified clinical 
protocol "Breast Cancer" (Order of the Ministry of Health 
of Ukraine No. 396 of June 30, 2015), in which mastopathy 
is organizationally attributed to precancerous pathology, 
which is detectable in mammological screening programs 
(physical, ultrasound and radiological with histological 
verification of the nature of the process in suspected BC), 
and women with any form of mastopathy are subject to 
mandatory treatment and preventive recovery [3]. 
In recent years, the approach to the treatment of 
precancerous diseases has been gradually changing, due to 
the emergence of a new unique and promising direction - 
"targeted therapy", based on the principles of targeted 
effects on the underlying molecular mechanisms 
underlying of this or that disease [1]. 
In the treatment of BC usually used several main 
classes of targeted drugs that provide control of the cell 
cycle: 1) affect the cellular estrogen receptors; 2) inhibit 
aromatase; 3) block the receptor of the human epidermal 
growth factor; 2 (HER; 2) and PARP; proteins, etc. [1]. 
The clinical protocol "Prevention and diagnosis of 
breast hormone diseases" (Order of the Ministry of Health 
of Ukraine No. 676) contains a list of recommended drugs 
for the prevention of breast tumours, which include 
sedative drugs; vitamins B1, B2, C, E, A, folic acid, 
multivitamins; antioxidants; immunocorrectors, 
adaptogens, drugs that improve digestive tract function and 
metabolism in the liver, dopamine receptor antagonists; 
GnRH analogues. 
All diffuse forms of mastopathy are subjected to 
conservative treatment. The general disadvantages of most 
drugs used today for the treatment of mastopathy can be 
attributed to the low effectiveness and focus only on 
alleviating symptoms, not correcting the problem as such. 
Not only the estrogens themselves but also their 
metabolites play an important role in the processes that 
trigger the proliferative diseases of the female reproductive 
system. It has been proved that estrone and estradiol make 
up 10-15% of the total amount of estrogen derivatives, and 
85-90% are metabolites of estrogens (mainly hydroxy 
derivatives). 
Many years of searching for chemical compounds 
that block the development of hyperplastic processes in 
hormone-dependent tissues have drawn the attention of 
scientists to indole derivatives. They have been found to 
enhance the expression of cytochrome P450-CYP1A1 
isoforms, which in turn is hydroxylated to hydroxyestrone 
form. It is established that this metabolite has 
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Materials and methods 
 In order to substantiate the use of the indole derivative - 
indomethacin - as an active pharmaceutical ingredient 
(API) in the complex gel for the treatment of mastopathy 
and prevention of malignant breast tumours, the domestic 
pharmaceutical market was studied for the presence of 
drugs with indomethacin in different dosage forms, 
different composition and presented by different countries 
and manufacturers (Fig. 1 – 3). 
 
Fig. 1. Distribution of indomethacin drugs by dosage forms 
 
Fig. 2. Distribution of indomethacin drugs by manufacturers 
 
Fig. 3. Distribution of indomethacin drugs by compound 
 
Results & discussion. As it shown in the data of 
fig. 1-3, most of the medicines available on the Ukrainian 
pharmaceutical market are complex soft dosage forms, 
mostly gels, presented by “Indovazin-Teva”, “Indovazine” 
manufactured by Balkanpharma-Troyan JSC, Bulgaria; 
“Indovenol” manufactured by PJSC “Borschagov 
Chemical and Pharmaceutical Plant”, Ukraine; complex 
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drugs “Troxovedol” manufactured by PJSC Viola 
Pharmaceutical Factory, Ukraine; complex medicines in 
the form of ointments “Indomethacin Plus” manufactured 
by PJSC “Chemical Factory Red Star”, Ukraine; 
“Indomethacin Sopharma” manufactured by JSC 
“Sopharma”, Bulgaria.  
Drugs in solid dosage forms are represented by 
enteric tablets "Indomethacin Zdorovya" manufactured by 
pharmaceutical company “Zdorovye”, “Indomethacin 
Sopharma” manufactured by JSC “Sopharma”, Bulgaria; 
tablets effervescent “Difmetre”, manufactured by “Abbott 
Labora GmbH”, Germany; suppositories “Indomethacin 
Sopharma” manufactured by JSC “Sopharma”, Bulgaria. 
Representative of liquid medicines there are eye drops 
“Indokolir 0.1%” manufactured by LLC “Valeant 
Pharmaceuticals”, Chauvin laboratory, France. 
The drugs are classified into different groups 
according to ATC classification: C05CA51 
“Vasoprotectives. Capillary stabilizing agents. 
Bioflavonoids. Rutoside, combinations”, M02AA “Anti-
inflammatory preparations, non-steroids for topical use”, 
M02AA23 “Anti-inflammatory preparations, non-steroids 
for topical use. Indometacin”, S01BC01 
“Ophthalmologicals. Anti-inflammatory agents, non-
steroids”, etc. 
Given the lack of complex drugs in the Ukrainian 
market in the form of gels, the composition and mechanism 
of action of which would make it possible to use them in 
the scheme of complex treatment of mastopathy, the task 
was to develop a soft dosage form that would provide a 
complex mechanism of action, taking into account 
pathogenetic links of the disease [7 - 10]. 
Due to the effectiveness of the use of indole 
derivatives in the treatment of various forms of 
mastopathy, it was decided to use it as a non-steroidal anti-
inflammatory component of the developing gel. 
A number of scientists (Drogovoz S.M., 
Derimedvid L.V., Shchokina K.G.) conducted a 
comparative study of the types of pharmacological action 
of NSAIDs and established ED50 for indometacin by the 
types of studied activity (Fig. 4 - 5) [11].  
As evidenced by the figure, the expressed level of 
antiproliferative, anti-exudative activity in the presence of 
inflammatory process, analgesic, infectious activity makes 
it possible to state that the use of indomethacin will provide 
the necessary pharmacological action in the treatment of 
mastopathy, taking into account polyethiology and 
pathogenicity. 
When studying the composition of drugs in the 
form of gels, presented on the domestic pharmaceutical 
market, it was found that the concentration of indometacin 
in their composition is 3% (gel “Indovazine”, “Indovazine 
Teva” and “Troxevenol”), 5% (ointment “Indomethacin 
plus”) and 10 % (ointment “Indomethacin Sopharma”). 
The last representative is used as an anti-rheumatic agent 
for joint diseases, so, in our opinion, in the further studies 
to consider the use of the specified NSAIDs is impractical. 
Given the sensitivity of the breast skin, as well as 
experimental studies to determine the therapeutic dose of 
the substance of other scientists, in the next stage it was 
rational to study the possibility of developing experimental 
samples of gel with an indomethacin concentration of 2.5 
to 5.5 %. The concentration interval of NSAIDs in the test 
samples was 0.5 % (Tab. 1). Previously, to select the 
concentration of indometacin in the developing of gel 
composition, biopharmaceutical studies were conducted to 
study the degree of its release from the developed gel base 
using the agar plate method and dialysis through a 
semipermeable membrane [8, 12]. 
The diameter of the coloured zones was 
determined by colour reaction with hydroxylamine 
hydrochloride and hydrochloric acid. The reagent was 
added to the agar gel, diffusing into which, indomethacin 
interacted, resulting in the formation of coloured areas of 
different diameter, having a purple-pink colour. 
The kinetics of indometacin release from the gel 
compositions were determined by the diffusion method 
through a semipermeable cellophane membrane (according 
to Kruvchinsky). Sampling of dialysate (5 ml) was 
performed at regular intervals, filling the environment with 
an equal amount of ethanol 95% (taking into account the 
solubility of indomethacin) (Fig. 6).  
In the course of the experiment we closely 
monitored the tightness of dialysis devices. All 
experiments were performed in 5 replicates, the results of 
the experiments were statistically processed using the 
Student's t-test with a confidence probability of 0.95. 
The quantitative content of indometacin was 
determined by the titrimetric method according to the 
requirements of SPhU v.2 [12]. 
The kinetic curves of indometacin release are 
shown in Fig. 7. 
According to the experimental data, the dynamics 
of indomethacin release from sample #4 are almost inferior 
to that from sample #3, and are not significantly different 
from that from sample #2, while the indomethacin release 
rate from samples #6 and #7 is much lower, similar to 
sample #4. This may be explained by the deterioration of 
the solubility of indometacin in the components of the 
substrate with increasing its concentration. More dynamic 
release of the active ingredient from sample # 4 will 
provide a prolonged and mild effect of the drug, reducing 
the possibility of side effects. 
Thus, we can consider a rational concentration of 
indomethacin 4% in terms of pharmacological and 
economic feasibility
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Fig. 4. Comparison of types of pharmacological activity of representatives of NSAIDs  
 
Fig. 5. ED50 for indometacin by type of activity 
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Fig. 6. An algorithm for experimental work to determine the effect of indomethacin concentration on the gel release 
process by dialysis through a semipermeable membrane
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1. The etiology of mastopathy, strategic directions of 
pharmaco-correction and mechanisms of action of drugs 
for its complex therapy have been investigated. 
2. The domestic pharmaceutical market was 
analysed for the presence of indomethacin medicines. The 
types of dosage forms, the countries of origin, the 
composition of drugs and the concentration of indometacin 
in them were determined. 
3. The spectrum and level of different types of 
indometacin activity have been studied, with which the 
expediency of its use for pathogenetic correction of 
mastopathy is substantiated. 
4. Biopharmaceutical studies have been conducted 
to study the degree of indometacin release from 
experimental combination gel samples for the treatment of 
mastopathy by agar gel diffusion and dialysis through a 
semi-permeable membrane. 
5. According to the results of the release kinetics 
analysis, the concentration of indometacin as the active 
pharmaceutical ingredient of the gel is proposed. 
 
Biopharmaceutical research on the choice of a non-
steroidal anti-inflammatory agent in the development 
of combination gel for mastopathy therapy 
Zuikina S. S, Vyshnevska L. I. 
According to the International Agency for Research on 
Cancer (IARC) at WHO, more than 1.7 million women are 
diagnosed with breast cancer annually. In Ukraine, 
according to the National Cancer Registry, in 2013, BC 
was first identified in 16,624 women (in 2012 – 16,660), 
which is 72.2 cases (in 2012 – 67) for every 100,000 
women in the country. The global death toll from this 
disease is growing and is killing more than 500,000 women 
worldwide annually. According to experts from the 
National Cancer Institute, a diagnosis of breast cancer by 
the end of 2020 may become a reality for almost 17% of 
Ukrainian women, which gives reason to view it as a 
socially significant epidemiological problem.The aim of 
the study was to substantiate the choice of NSAIDs and 
their concentration for use in the development of 
combination gel for the treatment of mastopathy and 
prevention of breast cancer. The methods of literary 
analysis, marketing research and biopharmaceutical 
methods in vitro were used. The results of marketing 
studies and pharmacological studies of the level and types 
of activity of NSAIDs allowed indometacin to be selected 
as the active pharmaceutical ingredient (API). According 
to the results of biopharmaceutical studies, the 
concentration of the active substance in the composition of 
the gel is established. 
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